198 related articles for article (PubMed ID: 22860174)
1. 3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)-mediated neuroprotective effects.
Scatena A; Fornai F; Trincavelli ML; Taliani S; Daniele S; Pugliesi I; Cosconati S; Martini C; Da Settimo F
ACS Chem Neurosci; 2011 Sep; 2(9):526-35. PubMed ID: 22860174
[TBL] [Abstract][Full Text] [Related]
2. 3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists.
Taliani S; Pugliesi I; Barresi E; Simorini F; Salerno S; La Motta C; Marini AM; Cosimelli B; Cosconati S; Di Maro S; Marinelli L; Daniele S; Trincavelli ML; Greco G; Novellino E; Martini C; Da Settimo F
J Med Chem; 2012 Feb; 55(4):1490-9. PubMed ID: 22257095
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.
Tebano MT; Pintor A; Frank C; Domenici MR; Martire A; Pepponi R; Potenza RL; Grieco R; Popoli P
J Neurosci Res; 2004 Jul; 77(1):100-7. PubMed ID: 15197743
[TBL] [Abstract][Full Text] [Related]
4. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.
Baraldi PG; Baraldi S; Saponaro G; Preti D; Romagnoli R; Piccagli L; Cavalli A; Recanatini M; Moorman AR; Zaid AN; Varani K; Borea PA; Tabrizi MA
J Med Chem; 2012 Jan; 55(2):797-811. PubMed ID: 22148859
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Offen D; Sherki Y; Melamed E; Fridkin M; Brenneman DE; Gozes I
Brain Res; 2000 Jan; 854(1-2):257-62. PubMed ID: 10784133
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of the A1 and A2A adenosine receptor prevents amyloid beta toxicity in neuroblastoma cells exposed to aluminum chloride.
Giunta S; Andriolo V; Castorina A
Int J Biochem Cell Biol; 2014 Sep; 54():122-36. PubMed ID: 25058312
[TBL] [Abstract][Full Text] [Related]
7. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385.
Wang Z; Che PL; Du J; Ha B; Yarema KJ
PLoS One; 2010 Nov; 5(11):e13883. PubMed ID: 21079735
[TBL] [Abstract][Full Text] [Related]
8. Toward PET imaging of A2B adenosine receptors: a carbon-11 labeled triazinobenzimidazole tracer: Synthesis and imaging of a new A2B PET tracer.
Petroni D; Giacomelli C; Taliani S; Barresi E; Robello M; Daniele S; Bartoli A; Burchielli S; Pardini S; Salvadori PA; Da Settimo F; Martini C; Trincavelli ML; Menichetti L
Nucl Med Biol; 2016 May; 43(5):309-17. PubMed ID: 27150034
[TBL] [Abstract][Full Text] [Related]
9. Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.
Alnouri MW; Jepards S; Casari A; Schiedel AC; Hinz S; Müller CE
Purinergic Signal; 2015 Sep; 11(3):389-407. PubMed ID: 26126429
[TBL] [Abstract][Full Text] [Related]
10. 2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.
Gao ZG; Mamedova LK; Chen P; Jacobson KA
Biochem Pharmacol; 2004 Nov; 68(10):1985-93. PubMed ID: 15476669
[TBL] [Abstract][Full Text] [Related]
11. C2-substituted quinazolinone derivatives exhibit A
Pieterse L; van der Walt MM; Terre'Blanche G
Bioorg Med Chem Lett; 2020 Aug; 30(16):127274. PubMed ID: 32631506
[TBL] [Abstract][Full Text] [Related]
12. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells.
Lappas CM; Rieger JM; Linden J
J Immunol; 2005 Jan; 174(2):1073-80. PubMed ID: 15634932
[TBL] [Abstract][Full Text] [Related]
13. 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor.
Palmer TM; Poucher SM; Jacobson KA; Stiles GL
Mol Pharmacol; 1995 Dec; 48(6):970-4. PubMed ID: 8848012
[TBL] [Abstract][Full Text] [Related]
14. Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A
Barresi E; Giacomelli C; Daniele S; Tonazzini I; Robello M; Salerno S; Piano I; Cosimelli B; Greco G; Da Settimo F; Martini C; Trincavelli ML; Taliani S
Bioorg Med Chem; 2018 Dec; 26(22):5885-5895. PubMed ID: 30415894
[TBL] [Abstract][Full Text] [Related]
15. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Presgraves SP; Borwege S; Millan MJ; Joyce JN
Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel 1,3,5-triazine as adenosine A
Masih A; Agnihotri AK; Srivastava JK; Pandey N; Bhat HR; Singh UP
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22659. PubMed ID: 33156955
[TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers.
Soriano A; Ventura R; Molero A; Hoen R; Casadó V; Cortés A; Fanelli F; Albericio F; Lluís C; Franco R; Royo M
J Med Chem; 2009 Sep; 52(18):5590-602. PubMed ID: 19711895
[TBL] [Abstract][Full Text] [Related]
18. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease.
Varani K; Vincenzi F; Tosi A; Gessi S; Casetta I; Granieri G; Fazio P; Leung E; MacLennan S; Granieri E; Borea PA
FASEB J; 2010 Feb; 24(2):587-98. PubMed ID: 19776336
[TBL] [Abstract][Full Text] [Related]
19. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.
Squarcialupi L; Colotta V; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Borea PA; Porta N; Ciancetta A; Moro S
Eur J Med Chem; 2014 Sep; 84():614-27. PubMed ID: 25063944
[TBL] [Abstract][Full Text] [Related]
20. Derivatives of benzimidazol-2-ylquinoline and benzimidazol-2-ylisoquinoline as selective A1 adenosine receptor antagonists with stimulant activity on human colon motility.
Cosimelli B; Taliani S; Greco G; Novellino E; Sala A; Severi E; Da Settimo F; La Motta C; Pugliesi I; Antonioli L; Fornai M; Colucci R; Blandizzi C; Daniele S; Trincavelli ML; Martini C
ChemMedChem; 2011 Oct; 6(10):1909-18. PubMed ID: 21796795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
